Effect of Antiadhesion Barrier Solution and Fibrin on Capsular Formation After Silicone Implant Insertion in a White Rat Model

Seung Geun Lee, Sang Dal Lee, Min Kuk Kim, Woo Sang Ryu, Seung Pil Jung, Sangmin Kim, Hoon Yub Kim, Eul Sik Yoon, Chul Hwan Kim, Seok Jin Nam, Jeoung Won Bae

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

No Level Assigned: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors http://www.springer.com/00266.

Introduction: One of the most serious complications of breast reconstruction and augmentation using silicone implants is capsular contracture. Several preventive treatments, including vitamin E, steroids, antibiotics, and cysteinyl leukotriene inhibitors, have been studied, and their clinical effects have been reported. However, the problem of capsular contracture has not yet been completely resolved. This study was performed to compare anti-adhesion barrier solution (AABS) and fibrin in their ability to prevent fibrotic capsule formation and simultaneously evaluated their effect when used in combination by capsular thickness analysis and quantitative analysis of matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and type I collagen within the fibrous capsule.

Materials and Methods: This study used female six-week-old Sprague-Dawley rats. Eighty rats were equally subdivided into the four following groups: AABS-treated, fibrin-treated, AABS and fibrin combined-treated, and untreated control groups. Each rat received two silicone chips under the panniculus carnosus muscle layer. The test materials were applied around the silicon chips. Four weeks later, the implantation sites including the skin and muscle were excised to avoid the risk of losing the fibrous capsule around the implants. The capsular thickness was analyzed by Masson’s trichrome stain. Quantitative analysis of type I collagen, MMPs, and TIMPs was performed by real-time PCR, Western blot, and zymography.

Results: The mean capsular thickness was 668.10 ± 275.12 μm in the control group, 356.97 ± 112.11 μm in the AABS-treated group, 525.96 ± 130.97 μm in the fibrin-treated group, and 389.24 ± 130.51 μm in the AABS and fibrin combined-treated group. Capsular thickness was significantly decreased in all experimental groups (p < 0.05). Capsular thickness was greater in the fibrin-treated group than in the AABS-treated group (p < 0.05). There was no statistically significant difference in capsular thickness between the AABS and fibrin combined-treated group and the AABS- or fibrin-treated group (p > 0.05). Compared to the control group, the experimental groups had significantly lower expressions of type I collagen and MMP-1 (p < 0.05), but there was no statistically significant difference in expressions of type I collagen and MMP-1 between the AABS-, fibrin-, and AABS and fibrin combined-treated groups (p > 0.05). The expressions of MMP-2 and TIMP-2 were not significantly different between the control and the experimental groups (p > 0.05).

Conclusion: AABS is more effective in reducing capsular thickness compared with fibrin treatment in a white rat model.

Original languageEnglish
Pages (from-to)162-170
Number of pages9
JournalAesthetic Plastic Surgery
Volume39
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Silicones
Fibrin
Matrix Metalloproteinase Inhibitors
Collagen Type I
Capsules
Tissue Inhibitor of Metalloproteinases
Control Groups
Evidence-Based Medicine
Implant Capsular Contracture
Tissue Inhibitor of Metalloproteinase-2
Muscles
Matrix Metalloproteinase 1
Mammaplasty
Manuscripts
Matrix Metalloproteinase 2
Contracture
Silicon
Vitamin E
Cadaver
Sprague Dawley Rats

Keywords

  • Collagen
  • Fibrin
  • Implant capsular contracture
  • MMPs
  • Silicone
  • TIMP

ASJC Scopus subject areas

  • Surgery

Cite this

Effect of Antiadhesion Barrier Solution and Fibrin on Capsular Formation After Silicone Implant Insertion in a White Rat Model. / Lee, Seung Geun; Lee, Sang Dal; Kim, Min Kuk; Ryu, Woo Sang; Jung, Seung Pil; Kim, Sangmin; Kim, Hoon Yub; Yoon, Eul Sik; Kim, Chul Hwan; Nam, Seok Jin; Bae, Jeoung Won.

In: Aesthetic Plastic Surgery, Vol. 39, No. 1, 01.01.2015, p. 162-170.

Research output: Contribution to journalArticle

Lee, Seung Geun ; Lee, Sang Dal ; Kim, Min Kuk ; Ryu, Woo Sang ; Jung, Seung Pil ; Kim, Sangmin ; Kim, Hoon Yub ; Yoon, Eul Sik ; Kim, Chul Hwan ; Nam, Seok Jin ; Bae, Jeoung Won. / Effect of Antiadhesion Barrier Solution and Fibrin on Capsular Formation After Silicone Implant Insertion in a White Rat Model. In: Aesthetic Plastic Surgery. 2015 ; Vol. 39, No. 1. pp. 162-170.
@article{de3d32484446464ba97fab1365cc8d72,
title = "Effect of Antiadhesion Barrier Solution and Fibrin on Capsular Formation After Silicone Implant Insertion in a White Rat Model",
abstract = "No Level Assigned: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors http://www.springer.com/00266.Introduction: One of the most serious complications of breast reconstruction and augmentation using silicone implants is capsular contracture. Several preventive treatments, including vitamin E, steroids, antibiotics, and cysteinyl leukotriene inhibitors, have been studied, and their clinical effects have been reported. However, the problem of capsular contracture has not yet been completely resolved. This study was performed to compare anti-adhesion barrier solution (AABS) and fibrin in their ability to prevent fibrotic capsule formation and simultaneously evaluated their effect when used in combination by capsular thickness analysis and quantitative analysis of matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and type I collagen within the fibrous capsule.Materials and Methods: This study used female six-week-old Sprague-Dawley rats. Eighty rats were equally subdivided into the four following groups: AABS-treated, fibrin-treated, AABS and fibrin combined-treated, and untreated control groups. Each rat received two silicone chips under the panniculus carnosus muscle layer. The test materials were applied around the silicon chips. Four weeks later, the implantation sites including the skin and muscle were excised to avoid the risk of losing the fibrous capsule around the implants. The capsular thickness was analyzed by Masson’s trichrome stain. Quantitative analysis of type I collagen, MMPs, and TIMPs was performed by real-time PCR, Western blot, and zymography.Results: The mean capsular thickness was 668.10 ± 275.12 μm in the control group, 356.97 ± 112.11 μm in the AABS-treated group, 525.96 ± 130.97 μm in the fibrin-treated group, and 389.24 ± 130.51 μm in the AABS and fibrin combined-treated group. Capsular thickness was significantly decreased in all experimental groups (p < 0.05). Capsular thickness was greater in the fibrin-treated group than in the AABS-treated group (p < 0.05). There was no statistically significant difference in capsular thickness between the AABS and fibrin combined-treated group and the AABS- or fibrin-treated group (p > 0.05). Compared to the control group, the experimental groups had significantly lower expressions of type I collagen and MMP-1 (p < 0.05), but there was no statistically significant difference in expressions of type I collagen and MMP-1 between the AABS-, fibrin-, and AABS and fibrin combined-treated groups (p > 0.05). The expressions of MMP-2 and TIMP-2 were not significantly different between the control and the experimental groups (p > 0.05).Conclusion: AABS is more effective in reducing capsular thickness compared with fibrin treatment in a white rat model.",
keywords = "Collagen, Fibrin, Implant capsular contracture, MMPs, Silicone, TIMP",
author = "Lee, {Seung Geun} and Lee, {Sang Dal} and Kim, {Min Kuk} and Ryu, {Woo Sang} and Jung, {Seung Pil} and Sangmin Kim and Kim, {Hoon Yub} and Yoon, {Eul Sik} and Kim, {Chul Hwan} and Nam, {Seok Jin} and Bae, {Jeoung Won}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00266-014-0436-x",
language = "English",
volume = "39",
pages = "162--170",
journal = "Aesthetic Plastic Surgery",
issn = "0364-216X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Effect of Antiadhesion Barrier Solution and Fibrin on Capsular Formation After Silicone Implant Insertion in a White Rat Model

AU - Lee, Seung Geun

AU - Lee, Sang Dal

AU - Kim, Min Kuk

AU - Ryu, Woo Sang

AU - Jung, Seung Pil

AU - Kim, Sangmin

AU - Kim, Hoon Yub

AU - Yoon, Eul Sik

AU - Kim, Chul Hwan

AU - Nam, Seok Jin

AU - Bae, Jeoung Won

PY - 2015/1/1

Y1 - 2015/1/1

N2 - No Level Assigned: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors http://www.springer.com/00266.Introduction: One of the most serious complications of breast reconstruction and augmentation using silicone implants is capsular contracture. Several preventive treatments, including vitamin E, steroids, antibiotics, and cysteinyl leukotriene inhibitors, have been studied, and their clinical effects have been reported. However, the problem of capsular contracture has not yet been completely resolved. This study was performed to compare anti-adhesion barrier solution (AABS) and fibrin in their ability to prevent fibrotic capsule formation and simultaneously evaluated their effect when used in combination by capsular thickness analysis and quantitative analysis of matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and type I collagen within the fibrous capsule.Materials and Methods: This study used female six-week-old Sprague-Dawley rats. Eighty rats were equally subdivided into the four following groups: AABS-treated, fibrin-treated, AABS and fibrin combined-treated, and untreated control groups. Each rat received two silicone chips under the panniculus carnosus muscle layer. The test materials were applied around the silicon chips. Four weeks later, the implantation sites including the skin and muscle were excised to avoid the risk of losing the fibrous capsule around the implants. The capsular thickness was analyzed by Masson’s trichrome stain. Quantitative analysis of type I collagen, MMPs, and TIMPs was performed by real-time PCR, Western blot, and zymography.Results: The mean capsular thickness was 668.10 ± 275.12 μm in the control group, 356.97 ± 112.11 μm in the AABS-treated group, 525.96 ± 130.97 μm in the fibrin-treated group, and 389.24 ± 130.51 μm in the AABS and fibrin combined-treated group. Capsular thickness was significantly decreased in all experimental groups (p < 0.05). Capsular thickness was greater in the fibrin-treated group than in the AABS-treated group (p < 0.05). There was no statistically significant difference in capsular thickness between the AABS and fibrin combined-treated group and the AABS- or fibrin-treated group (p > 0.05). Compared to the control group, the experimental groups had significantly lower expressions of type I collagen and MMP-1 (p < 0.05), but there was no statistically significant difference in expressions of type I collagen and MMP-1 between the AABS-, fibrin-, and AABS and fibrin combined-treated groups (p > 0.05). The expressions of MMP-2 and TIMP-2 were not significantly different between the control and the experimental groups (p > 0.05).Conclusion: AABS is more effective in reducing capsular thickness compared with fibrin treatment in a white rat model.

AB - No Level Assigned: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors http://www.springer.com/00266.Introduction: One of the most serious complications of breast reconstruction and augmentation using silicone implants is capsular contracture. Several preventive treatments, including vitamin E, steroids, antibiotics, and cysteinyl leukotriene inhibitors, have been studied, and their clinical effects have been reported. However, the problem of capsular contracture has not yet been completely resolved. This study was performed to compare anti-adhesion barrier solution (AABS) and fibrin in their ability to prevent fibrotic capsule formation and simultaneously evaluated their effect when used in combination by capsular thickness analysis and quantitative analysis of matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and type I collagen within the fibrous capsule.Materials and Methods: This study used female six-week-old Sprague-Dawley rats. Eighty rats were equally subdivided into the four following groups: AABS-treated, fibrin-treated, AABS and fibrin combined-treated, and untreated control groups. Each rat received two silicone chips under the panniculus carnosus muscle layer. The test materials were applied around the silicon chips. Four weeks later, the implantation sites including the skin and muscle were excised to avoid the risk of losing the fibrous capsule around the implants. The capsular thickness was analyzed by Masson’s trichrome stain. Quantitative analysis of type I collagen, MMPs, and TIMPs was performed by real-time PCR, Western blot, and zymography.Results: The mean capsular thickness was 668.10 ± 275.12 μm in the control group, 356.97 ± 112.11 μm in the AABS-treated group, 525.96 ± 130.97 μm in the fibrin-treated group, and 389.24 ± 130.51 μm in the AABS and fibrin combined-treated group. Capsular thickness was significantly decreased in all experimental groups (p < 0.05). Capsular thickness was greater in the fibrin-treated group than in the AABS-treated group (p < 0.05). There was no statistically significant difference in capsular thickness between the AABS and fibrin combined-treated group and the AABS- or fibrin-treated group (p > 0.05). Compared to the control group, the experimental groups had significantly lower expressions of type I collagen and MMP-1 (p < 0.05), but there was no statistically significant difference in expressions of type I collagen and MMP-1 between the AABS-, fibrin-, and AABS and fibrin combined-treated groups (p > 0.05). The expressions of MMP-2 and TIMP-2 were not significantly different between the control and the experimental groups (p > 0.05).Conclusion: AABS is more effective in reducing capsular thickness compared with fibrin treatment in a white rat model.

KW - Collagen

KW - Fibrin

KW - Implant capsular contracture

KW - MMPs

KW - Silicone

KW - TIMP

UR - http://www.scopus.com/inward/record.url?scp=84921910945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921910945&partnerID=8YFLogxK

U2 - 10.1007/s00266-014-0436-x

DO - 10.1007/s00266-014-0436-x

M3 - Article

C2 - 25516275

AN - SCOPUS:84921910945

VL - 39

SP - 162

EP - 170

JO - Aesthetic Plastic Surgery

JF - Aesthetic Plastic Surgery

SN - 0364-216X

IS - 1

ER -